Sarcoma Clinical Trials

Researchers discussing Sarcoma in a lab

Patients with sarcoma can consider clinical trials to expand their range of treatment options. In a clinical trial, researchers provide one group of patients with an investigational therapy, such as a novel chemotherapy drug, while providing a second group of patients with the best treatment that is currently available. This helps patients access the newest treatments before they are offered to the public, while helping researchers determine which treatments produce the best outcomes and the fewest side effects.

Recent sarcoma clinical trials have investigated treatments such as:

  • New medications for chemotherapy-resistant sarcomas
  • New drug combinations for sarcomas that cannot be surgically removed
  • Proton therapy as an alternative to X-ray-based radiation therapy
  • Peripheral stem cell transplantation as a potential sarcoma treatment
  • Antibody-based treatments for recurrent sarcomas
  • Less toxic treatments for pediatric sarcoma patients

Other sarcoma clinical trials have explored risk factors, screening methods, preventive options and techniques to improve the likelihood of early diagnosis. For instance, researchers have linked several genetic syndromes to an increased risk of developing sarcoma, and this information has led to better awareness for these individuals. Through clinical trials, researchers are improving options not just for current patients, but for every individual who will face a sarcoma diagnosis in the future.

As part of our commitment to ongoing research, Moffitt Cancer Center offers an extensive range of clinical trials, with options for patients with many different types and stages of sarcoma. These trials are overseen by our expert oncologists and research professionals; careful monitoring ensures that every participant receives the best possible treatment for his or her needs. In recognition of our extensive research efforts, the National Cancer Institute awarded Moffitt Cancer Center with its prestigious Comprehensive Cancer Center designation.

For more information about sarcoma clinical trials, or to enroll in one of Moffitt Cancer Center’s ongoing trials, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. Referrals are not required to seek treatment at Moffitt and participate in our clinical trials.

Helpful Links:


calledFromCancerPage=True - substr=

Open Clinical Trials:

Showing of 50


Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults

Disease Site: Ewing's sarcoma, Osteosarcoma, Rhabdomyosarcoma, Any Site

View Trial Details


Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) with and without Topotecan and Cyclophosphamide in Patients with Relapsed or Refractory Ewing Sarcoma and Select Sarcomas

Disease Site: Ewing's sarcoma, Any Site

View Trial Details


A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma

Disease Site: Soft Tissue

View Trial Details


A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma

Disease Site: Any Site, Osteosarcoma

View Trial Details


A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

Disease Site: Any Site, Bones and Joints, Breast, Esophagus, Larynx, Lung, Other Respiratory and Intrathoracic Organs, Soft Tissue

View Trial Details


A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD 1 Study)

Disease Site: Any Site

View Trial Details


Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma

Disease Site: Rhabdomyosarcoma, Bones and Joints

View Trial Details


Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) or Photon (IMRT) with Simultaneously Integrated Boost to the High Margin for Retroperitoneal Sarcomas

Disease Site: Anal, Colon, Kidney, Other genitourinary, Pancreas, Rectum, Sarcoma

View Trial Details


A Multicenter Phase II Trial of Paclitaxel with and without Nivolumab in Taxane Naïve, and Nivolumab and Cabozantinib in Taxane Pre-treated Subjects with Angiosarcoma

Disease Site: Any Site, Soft Tissue

View Trial Details


Phase 2 Clinical Trial of Radiomic Habitat-Directed Radiation Dose Escalation for High-Grade Soft Tissue Sarcoma

Disease Site: Soft Tissue

View Trial Details


A Phase 3, Randomized, Double-Blind, Active- Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients

Disease Site: Bones and Joints, Myelofibrosis

View Trial Details


A Phase I/II Study of TTI-621 in Combination with Doxorubicin in Patients with Unresectable or Metastatic High-Grade Leiomyosarcoma

Disease Site: Soft Tissue

View Trial Details